AndrewA.WolffMDFACC

Cardiology • South San Francisco, CA

Adult Congenital Heart Disease

Chief Medical Officer & Senior Vice President, Clinical Research & Development, Cytokinetics, Inc.

Join to view full profile

Dr. Wolff is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Wolff's full profile

Already have an account?

Office
Cytokinetics, Inc.
280 East Grand Avenue
South San Francisco, CA 94080
Phone+1 605-624-3008
Is this information wrong?

Education & Training

University of California (San Francisco)Fellowship, Cardiovascular Disease, 1984 - 1987
NYU Grossman School of MedicineResidency, Internal Medicine, 1981 - 1984
Washington University/B-JH/SLCH ConsortiumInternship, Internal Medicine, 1980 - 1981
Washington University in St. Louis School of MedicineClass of 1980

Certifications & Licensure

CA State Medical License 1985 - 2024
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Cardiovascular Disease

Awards, Honors, & Recognition

Fellow (FACC) American College of Cardiology

Publications & Presentations

PubMed

2 citations
MiToS and King's staging as clinical outcome measures in ALS: a retrospective analysis of the FORTITUDE-ALS trial.
Paulos Gebrehiwet, Lisa Meng, Stacy A Rudnicki, Phil Sarocco, Jenny Wei, Andrew A Wolff, Adriano Chiò, Jinsy A Andrews, Angela Genge, Carlayne E Jackson, Noah Lechtzin...> ;Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 2023 May 1
2 citations
Prescription and acceptance of durable medical equipment in FORTITUDE-ALS, a study of reldesemtiv in ALS: post hoc analyses of a randomized, double-blind, placebo-cont...
Stacy A. Rudnicki, Jinsy A. Andrews, Angela Genge, Carlayne E. Jackson, Noah Lechtzin, Timothy M. Miller, Bettina M. Cockroft, Fady I. Malik, Lisa Meng, Jenny Wei, And...> ;Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 2021 Jul 5
3 citations
Correction to: Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating Study.
Stacy A. Rudnicki, Jinsy A. Andrews, Tina Duong, Bettina M. Cockroft, Fady I. Malik, Lisa Meng, Jenny Wei, Andrew A. Wolff, Angela Genge, Nicholas E. Johnson, Carolina...> ;Neurotherapeutics. 2021 Jul 1
1 citations
Noninvasive ventilation use by patients enrolled in VITALITY-ALS.
Stacy A. Rudnicki, Jinsy A. Andrews, Amy Bian, Bettina M. Cockroft, Merit Cudkowicz, Orla Hardiman, Fady I. Malik, Lisa Meng, Andrew A. Wolff, Jeremy M. Shefner> ;Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 2021 Apr 1
18 citations
Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating Study.
Stacy A. Rudnicki, Jinsy A. Andrews, Tina Duong, Bettina M. Cockroft, Fady I. Malik, Lisa Meng, Jenny Wei, Andrew A. Wolff, Angela Genge, Nicholas E. Johnson, Carolina...> ;Neurotherapeutics. 2021 Feb 23
33 citations
A phase III trial of tirasemtiv as a potential treatment for amyotrophic lateral sclerosis
Jeremy M. Shefner, Merit Cudkowicz, Orla Hardiman, Bettina M Cockcroft, Jacqueline H. Lee, Fady I. Malik, Lisa Meng, Stacy A. Rudnicki, Andrew A. Wolff, Jinsy A. Andrews> ;Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 2019 May 13
45 citations
Association Between Decline in Slow Vital Capacity and Respiratory Insufficiency, Use of Assisted Ventilation, Tracheostomy, or Death in Patients With Amyotrophic Late...
Jinsy A. Andrews, Lisa Meng, Sarah Kulke, Stacy A. Rudnicki, Andrew A. Wolff, Michael E. Bozik, Fady I. Malik, Jeremy M. Shefner> ;JAMA Neurology. 2018 Jan 1
5 citations
Relationships between slow vital capacity and measures of respiratory function on the ALSFRS-R.
Carlayne E. Jackson, Mamede de Carvalho, Angela Genge, Terry Heiman-Patterson, Jeremy M. Shefner, Jenny Wei, Andrew A. Wolff> ;Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 2018 Oct 31
48 citations
CK-2127107 amplifies skeletal muscle response to nerve activation in humans.
Jinsy A. Andrews, Timothy M. Miller, Vipin Vijayakumar, Randall Stoltz, Joyce K. James, Lisa Meng, Andrew A. Wolff, Fady I. Malik> ;Muscle & Nerve. 2018 May 1
20 citations
VITALITY-ALS, a phase III trial of tirasemtiv, a selective fast skeletal muscle troponin activator, as a potential treatment for patients with amyotrophic lateral scle...
Jinsy A. Andrews, Merit Cudkowicz, Orla Hardiman, Lisa Meng, Amy Bian, Jacqueline H. Lee, Andrew A. Wolff, Fady I. Malik, Jeremy M. Shefner> ;Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 2018 Feb 6
15 citations
Profile of medical care costs in patients with amyotrophic lateral sclerosis in the Medicare programme and under commercial insurance.
Lisa Meng, Amy Bian, Scott Jordan, Andrew A. Wolff, Jeremy M. Shefner, Jinsy A. Andrews> ;Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 2018 Jan 2
156 citations
Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study.
John R. Teerlink, G. Michael Felker, John J.V. McMurray, Piotr Ponikowski, Marco Metra, Gerasimos Filippatos, Justin A. Ezekowitz, Kenneth Dickstein, John G.F. Cleland...> ;Journal of the American College of Cardiology. 2016 Mar 29
31 citations
A randomized, placebo-controlled, double-blind phase IIb trial evaluating the safety and efficacy of tirasemtiv in patients with amyotrophic lateral sclerosis.
Jeremy M. Shefner, Andrew A. Wolff, Lisa Meng, Amy Bian, Jacqueline H. Lee, Donna Barragan, Jinsy A. Andrews> ;Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 2016 Mar 16
9 citations
The addition of granulocyte-colony stimulating factor shifts the dose limiting toxicity and markedly increases the maximum tolerated dose and activity of the kinesin s...
Owen A. O'Connor, John F. Gerecitano, Henrik Van Deventer, John D. Hainsworth, Kelly Zullo, Khalil G. Saikali, J. Seroogy, Andrew A. Wolff, Rafael D. Escandon> ;Leukemia & Lymphoma. 2015 Feb 10
54 citations
Safety and Tolerability of Omecamtiv Mecarbil During Exercise in Patients With Ischemic Cardiomyopathy and Angina
Barry H. Greenberg, Willis Chou, Khalil G. Saikali, Rafael D. Escandon, Jacqueline H. Lee, Michael M. Chen, Tatyana Treshkur, Irakli Megreladze, Scott M. Wasserman, Pa...> ;JACC. Heart Failure. 2015 Jan 1
24 citations
Tirasemtiv amplifies skeletal muscle response to nerve activation in humans.
Richard Hansen, Khalil G. Saikali, Willis Chou, Alan J. Russell, Michael M. Chen, Vipin Vijayakumar, Randall Stoltz, Stéphane Baudry, Roger M. Enoka, David J. Morgans,...> ;Muscle & Nerve. 2014 Dec 1
Letter: Herbal hepatotoxicity--an update on traditional Chinese medicine preparations; authors' reply.
Teschke R, Wolff A, Frenzel C, Schulze J> ;Aliment. Pharmacol. Ther.. 2014-09-01
Review article: Herbal hepatotoxicity--an update on traditional Chinese medicine preparations.
Teschke R, Wolff A, Frenzel C, Schulze J> ;Aliment. Pharmacol. Ther.. 2014-07-01
6 citations
Effect of tirasemtiv, a selective activator of the fast skeletal muscle troponin complex, in patients with peripheral artery disease
Timothy A. Bauer, Andrew A. Wolff, Alan T. Hirsch, Lisa L Meng, Kevin Rogers, Fady I. Malik, William R. Hiatt> ;Vascular Medicine. 2014 May 28
12 citations
The relationship between tirasemtiv serum concentration and functional outcomes in patients with ALS.
Jeremy M. Shefner, Andrew A. Wolff, Lisa Meng> ;Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 2013 Nov 1
26 citations
A study to evaluate safety and tolerability of repeated doses of tirasemtiv in patients with amyotrophic lateral sclerosis
Jeremy M. Shefner, Mary Lou Watson, Lisa Meng, Andrew A. Wolff, Neals, Cytokinetics Study Team> ;Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 2013 Nov 1
31 citations
Safety, tolerability and pharmacodynamics of a skeletal muscle activator in amyotrophic lateral sclerosis
Jeremy M. Shefner, Jesse M. Cedarbaum, Merit Cudkowicz, Nicholas J. Maragakis, Jacqueline H. Lee, Drew Jones, Mary Lou Watson, Katy Mahoney, Michael Chen, Khalil G. Sa...> ;Amyotrophic Lateral Sclerosis. 2012 Aug 16
30 citations
Phase I dose-escalation and pharmacokinetic study of ispinesib, a kinesin spindle protein inhibitor, administered on days 1 and 15 of a 28-day schedule in patients wit...
Henry L. Gomez, Manuel Philco, Patricia Pimentel, Miriam Kiyan, Maria Laura Monsalvo, M. Conlan, Khalil G. Saikali, Michael M. Chen, J. Seroogy, Andrew A. Wolff, Rafae...> ;Anti-Cancer Drugs. 2012 Mar 1
243 citations
The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ran...
John G.F. Cleland, John R. Teerlink, Roxy Senior, Evgeny M. Nifontov, John Murray, Chim C. Lang, Vitaly A. Tsyrlin, Barry H. Greenberg, Jamil Mayet, Darrel P. Francis,...> ;Lancet. 2011 Aug 20
184 citations
Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study
John R. Teerlink, Cyril P. Clarke, Khalil G. Saikali, Jacqueline H. Lee, Michael M. Chen, Rafael D. Escandon, Lyndsey Elliott, Rachel Bee, Mohammad R. Habibzadeh, Jona...> ;Lancet. 2011 Aug 20
Join now to see all

Professional Memberships

American College of Cardiology - ACC
Member